Introduction: Cardiovascular complications are a major cause of morbidity and mortality in patients with uncontrolled acromegaly. However, there are no published reports of an increased risk of venous thromboembolism (VTE) in such patients. We report three patients with uncontrolled acromegaly who presented with VTE.
Introduction
Uncontrolled acromegaly is associated with an increased risk of cardiovascular (CV) abnormalities such as hypertension, left ventricular hypertrophy (LVH), endothelial dysfunction and cardiomyopathy. [1] In fact, CV complications constitute the leading cause of morbidity and mortality in patients with acromegaly. [2] Recent reports have suggested that changes in the coagulation and fibrinolytic system may also play a role in the pathogenesis of CV disease in acromegaly. [3] [4] [5] To date, there are no published reports of an increased risk of venous thromboembolism (VTE) in acromegaly. We report three cases of patients with uncontrolled acromegaly who presented with extensive VTE.
Case Reports Case 1
A 52-year-old Caucasian male presented with typical phenotypic features of acromegaly in December 2009. Baseline serum IGF-1 and growth hormone (GH) levels were 1220 mcg/l (n 87-238) and 54.1 mcg/l (n <1 mcg/l), respectively; nadir GH after an oral glucose tolerance test was 29.3 mcg/l. Magnetic resonance imaging (MRI) of the sella revealed a 1.4 cm pituitary adenoma extending into the right cavernous sinus. He underwent transsphenoidal (TSP) tumour resection in June 2011, which led to a significant reduction in serum IGF-1, albeit without ORIGINAL ARTICLE J Cancer Allied Spec 2015;1(1):6 normalisation, at 15-20 % above the upper limit of normal (ULN). Follow-up MRI revealed a small residual tumour and the patient was offered repeat surgery or radiation therapy, which he declined. Due to the absence of medical coverage for somatostatin analogue therapy, cabergoline or pegvisomant, pharmacologic therapy with bromocriptine (10 mg daily) was initiated. He was unable to tolerate a larger dose due to nausea and dizziness. There was a slight reduction in his serum IGF-1, but it has remained uncontrolled, with serum IGF-1 consistently between 10 and 13% above ULN. To date, he declines further medical intervention. In September 2012, he presented with acute chest pain and shortness of breath and was subsequently diagnosed with a right upper lobe pulmonary embolism on computed tomography (CT) pulmonary angiography. No other risk factors for thromboembolism such as immobility, recent travel, malignancy or family history of VTE were identified. Anticoagulation with low molecular weight heparin was initiated until adequate warfarin therapy was established; he currently remains on a daily dose of 10 mg. A colonoscopy was performed in October 2012 which revealed three benign hyperplastic polyps and an echocardiogram showed mild diastolic left ventricular dysfunction but preserved systolic function. Thrombophilia screen [ Table 1 ] revealed the following results: Fibrinogen 3.81 g/L (n = 2.15-4.79), negative D-Dimer (negative < 200 ng/mL), protein C 1.03 U/mL (n = 0.74-1.64), protein S 0.66 U/mL (n = 0.7-1.47) and negative Factor V Leiden (FVL) and prothrombin gene mutations. 
Discussion
VTE can be associated with significant adverse outcomes if not promptly recognised, whereas timely initiation of anticoagulation therapy significantly reduces early morbidity and mortality. [6] Several studies have shown that patients with acromegaly have abnormalities in the coagulation and fibrinolytic systems that could potentially predispose to increased risk of VTE. [3] [4] [5] 7, 8] Plasma fibrinogen, an important clotting protein produced in the liver, has been reported to be significantly elevated in individuals with active acromegaly compared with healthy controls and plasma fibrinogen levels have a positive correlation with serum IGF-1. [3] Remission of acromegaly with surgery or medical therapy is associated with a reduction in plasma fibrinogen levels. [3] Another study [4] assessed coagulation markers in 22 patients with active acromegaly and reported elevated levels of fibrinogen, tissue plasminogen activator (t-PA) and PA inhibitor-1 (PAI-1) while protein S activity and tissue factor plasminogen inhibitor were decreased in these patients compared with healthy controls, potentially creating a pro-thrombotic environment. Elevated PAI-I is both an independent risk factor for VTE and the major determinant of elevated plasma clot lysis time, increasing VTE risk even after adjusting for other coagulation and ORIGINAL ARTICLE J Cancer Allied Spec 2015;1(1):6 fibrinolytic markers. [7] However, with the exception of fibrinogen and protein S, the association between most other coagulation and fibrinolysis markers described above and VTE is inconsistent and, consequently, they are not measured in routine thrombophilia screening. [8] In our patients, the thrombophilia screen was positive for homozygous and heterozygous FVL mutation in cases 2 and 3. This mutation is known to be associated with an increased risk of VTE in both heterozygous and homozygous individuals. [9] We were unable to find any association between acromegaly and FVL in a comprehensive MEDLINE search of the English language literature, using the keywords: "Acromegaly," "thrombosis," "coagulation" and "FVL." The two episodes of DVT post-surgery in case 3 represent an additional risk factor for VTE whilst the slightly low protein S level in case 1 and weakly positive lupus anticoagulant ratio in case 2 are not diagnostic of thrombophilia and are likely clinically unimportant.
Malignancy is one of the major risk factors for VTE, but the associated risk is dependent on the type and staging of the tumour as well as therapeutic modalities. [10] Occasionally, VTE can be the preceding manifestation of an occult malignancy. [11] Several recent studies have shown that patients with acromegaly are at increased risk of developing colon, thyroid and urogenital malignancies. [12] [13] [14] Consequently, in patients with acromegaly, colonoscopy is recommended for screening of colon cancer. [15, 16] Furthermore, acromegaly might be a component of other disorders such as multiple endocrine neoplasia type 1, McCune-Albright syndrome or other genetic syndromes in which additional tumours in other organs may coexist and therefore potentially increase the risk of VTE. [17] Patients with pituitary tumours who have received conventional radiation therapy also have a higher risk of developing secondary brain tumours. [18] Although the presence of occult malignancy is exceedingly difficult to exclude, we were unable to find any evidence of malignancy despite thorough clinical examination, diagnostic colonoscopy and extensive imaging studies including ultrasound and CT scan of the chest, abdomen and pelvis.
Congestive heart failure (CHF), found in some patients with long-standing uncontrolled acromegaly, has also been reported to increase the risk of VTE. [19] Blood stasis, chronic inflammatory-mediated endothelial dysfunction and reduced mobility are speculated to be among the potential underlying mechanisms. [19, 20] In one retrospective case-control study, the risk of VTE was significantly elevated in CHF patients with ejection fraction (EF) of <20% compared with those having EF >45%. [19] The slight increase in VTE risk in the setting of preserved EF is thought to be due to the potential presence of diastolic dysfunction or right ventricular failure. [19] Echocardiogram results in all of our cases showed normal EF with no findings of right-sided heart failure or any other significant abnormalities to account for VTE [ Table 2 ]. Two of our patients had previous radiation treatment and developed recurrence of VTE shortly after the addition of pegvisomant. It is unclear if localised sellar irradiation is associated with an increased risk of VTE. Medical therapy with somatostatin analogues and pegvisomant has not been reported to cause VTE. Previously a small study in 5 healthy individuals who were given a 3-day treatment of pegvisomant showed decreased levels of VW antigen, but no changes in fibrinogen, factor VIII, PAI-I, t-PA or other coagulation markers were observed. [21] Furthermore, data from the ACROSTUDY, a surveillance study of almost 1300 patients on pegvisomant for a mean of 2.3 years, did not report an increased risk of VTE. [22] FVL mutation is detected in about 25% of patients with VTE and is considered the most common thrombophilic disorder. [9] The overall prevalence has been reported to be approximately 5% in Caucasian Americans, 3-15% in Europeans and it is considered rare among Asians. [23, 24] Whether this mutation is commoner in patients with acromegaly is not known. It is noteworthy that all three patients had longstanding uncontrolled acromegaly. Whether uncontrolled acromegaly simply enhances the risk of VTE in patients with pre-existing thrombophilic disorders, acts as an independent risk factor or is associated with an increased risk of other thrombophilic disorders, remains unclear. Presence of FVL mutation could potentially confound the association between acromegaly and increased VTE risk. Further studies are required to systematically assess this finding to appropriately counsel patients with acromegaly.
Conclusion
To the best of our knowledge, these cases constitute the first reported clinical association between active acromegaly and venous thrombosis. Possible explanations may include the presence of hereditary thrombophilia, an effect of GH or IGF-1 on the coagulation and fibrinolytic system, cardiac abnormalities or yet undiagnosed malignancy. Further studies should be conducted to assess this association.
